Free tool
FAERS Monitor: Dovato
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211994 or its brand name (Dovato, Dolutegravir Sodium, Lamivudine). Reports on generic versions are filed under their own applications.
Reports
3,600
Serious
1,372
38% of reports
Hospitalization
435
Death reported
120
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue1,096
- inappropriate schedule of product administration256
- product dose omission in error224
- product use issue195
- anxiety155
- pain142
- drug ineffective137
- rash126
- fatigue122
- viral load increased121
- pathogen resistance119
- off label use110
- intentional dose omission109
- emotional distress102
- incorrect dose administered98
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 90 |
| 2020 | 214 |
| 2021 | 306 |
| 2022 | 546 |
| 2023 | 865 |
| 2024 | 761 |
| 2025 | 577 |
| 2026 | 228 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| viral load increasedSignal | 121 | 187.9 | 157.3 | 21,620 |
| pathogen resistanceSignal | 119 | 77.3 | 64.7 | 8,771 |
| product dose omission in errorSignal | 224 | 46.6 | 41.0 | 9,879 |
| intentional dose omissionSignal | 109 | 22.4 | 18.6 | 2,204 |
| product dose omission issueSignal | 1,096 | 21.9 | 20.8 | 22,015 |
| inappropriate schedule of product administrationSignal | 256 | 8.3 | 7.4 | 1,651 |
| product use issueSignal | 195 | 6.1 | 5.3 | 827 |
| emotional distressSignal | 102 | 4.9 | 4.1 | 317 |
| anxietySignal | 155 | 3.2 | 2.7 | 233 |
| incorrect dose administeredSignal | 98 | 2.5 | 2.1 | 88 |
| rash | 126 | 1.7 | 1.4 | 35 |
| pain | 142 | 1.4 | 1.1 | 13 |
| fatigue | 122 | 0.9 | 0.8 | 1 |
| off label use | 110 | 0.7 | 0.6 | 11 |
| drug ineffective | 137 | 0.6 | 0.5 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.